Retatrutide is an investigational triple incretin receptor agonist that targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously
At a 70% price reduction, GLP-1RA is predicted to be cost-effective compared to non-SGLT2i standard-of-care therapies (cost-effectiveness ratio [CER] of $22,700)
Discuss Dose-Related Symptoms With a Clinician Contact the prescriber if headaches repeatedly follow injections or dose increases, persist despite basic measures, or interfere with daily activities
Serial sections of the median eminence of the hypothalamus were used for analysis (612 sections per staining method, spaced 150 m apart)
he was in his mid-30s, didnt smoke or drink, and considered himself healthy